611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
Many High-Risk Patients Don't Know They Need Follow-Up ColonoscopyAlmost 90,000 Young American Adults Will Get Cancer This Year: ReportCoffee May Slow Spread of Colon CancerAHA News: Immune-Boosting Cancer Treatment May Pose Cardiovascular RiskWhy Do Black Men Still Fare Worse With Prostate Cancer?No Link Found Between Blood Pressure Meds and Cancer: StudyCatch Prostate Cancer Early – It Could Save Your Life'Spare Tire' Might Up a Man's Prostate Cancer RiskCancer Radiation Can Safely Proceed During COVID-19 Pandemic: StudyMany Thyroid Cancer Ultrasound Scans UnnecessaryCan Women With Early Breast Cancer Skip Post-Op Radiation?Delaying Prostate Cancer Radiation Won't Lower Survival OddsBetter Treatments Bring Better Survival After Lung CancerCould Daily Low-Dose Aspirin Hasten Cancer in Seniors?Many Older Americans Getting Cancer Screens They Don't Need: StudyCancer Diagnoses Plunge as Americans Avoid Screening During PandemicAggressive Cancer Diagnosed for First Time in a DinosaurFew U.S. Women Know About Cancer That Develops Near Breast Implants: StudyTecartus Approved for Treatment of Mantle Cell LymphomaBlood Test Might Spot Cancer Years EarlierFor Cancer Patients, Getting COVID-19 Raises Death Risk 16-FoldKeep Flossing: Study Ties Gum Disease to Higher Cancer RiskTough Decisions as COVID-19 Causes Cancer Surgery DelaysHow to Protect Yourself From the Sun's Harmful UV RaysBlacks Underrepresented in Cancer Drug Trials: StudyNew Guidelines Could Double Number Eligible for Lung Cancer ScreeningBreast Cancer Caught Earlier in U.S. States With Expanded Medicaid: StudyObamacare Helps Poorer Americans Spot Cancer Earlier: StudyCommon Blood Pressure Meds May Lower Colon Cancer RiskHow Insurance Plans Keep Black Patients From Cancer CareStatins Tied to Significantly Lower Death Rate From Ovarian CancerNew Blood Test May Improve Liver Cancer ScreeningCancer Patients Less Likely to Be Prescribed Heart Meds: StudyBreast Cancer Takes Big Financial Toll on Some Young PatientsLoving Partners May Be Key to Breast Cancer Survivors' Health'Lab-on-a-Chip' Blood Test Could Spot Breast Cancer EarlyBlack Melanoma Patients Face Treatment Delays: StudyLatest in Cancer Prevention: Move More, Ditch Beer and BaconAt-Home Gene Test for Breast, Ovarian Cancers Looks EffectiveDrug Could Boost Survival From Lung Cancer Affecting Non-SmokersProtect Yourself From Sun to Prevent Skin CancerVery Early-Stage Breast Cancer Ups Long-Term Odds for Invasive Tumors: StudyHydroxychloroquine May Worsen Odds for Cancer Patients With COVID-19Tumors Have Their Own Bacterial Colonies That Could Guide Cancer Care'Major Financial Hardship' Hits Most Patients Battling Advanced Colon CancerAs Summer Starts, Sun Safety Slashes Skin Cancer RiskChild's Cancer Doesn't Raise Parents' Divorce Risk, Curb Plans for More Kids: StudyWith PSA Test Out of Favor, Cases of Advanced Prostate Cancer Are RisingBlack and White Women Share the Same Genetic Risk for Breast CancerKids With Cancer Not at Greater Risk for Severe COVID-19
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk

HealthDay News
by -- E.J. Mundell
Updated: Feb 14th 2020

new article illustration

THURSDAY, Feb. 13, 2020 (HealthDay News) -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S. market.

Eisai Inc. has already "submitted a request to voluntarily withdraw the drug," Dr. Janet Woodcock, who directs the FDA's Center for Drug Evaluation and Research, noted in a statement issued Thursday.

Now, "we're taking steps to notify the public," she said, adding that "our review of the full clinical trial results shows that the potential risk of cancer associated with the drug outweighs the benefit of treatment."

Woodcock said the FDA is advising that "patients should stop using the medication Belviq and Belviq XR [lorcaserin] and talk to their health care professionals about other treatment options for weight loss. Health care professionals should stop prescribing and dispensing Belviq and Belviq XR."

The agency first announced that Belviq might have links to cancer in a communication issued Jan 15.

At the time, the FDA said "we cannot conclude that lorcaserin contributes to the cancer risk," but "wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review."

That review appears to have led to calls for the voluntary withdrawal of the medication.

Belviq increases feelings of fullness so that people eat less. It's available as a tablet (Belviq) and an extended-release tablet (Belviq XR).

According to the FDA, Belviq was first approved in 2012 as an add-on therapy to help aid weight loss, along with diet and exercise, in people who were obese or overweight.

Contingent on approval, the FDA ordered a randomized, placebo-controlled trial be conducted involving 12,000 people tracked for more than five years.

The trial wrapped up in June 2018, and the data showed that while 7.1% of those taking a "dummy" placebo developed cancer, that number rose to 7.7% among those taking Belviq.

"A range of cancer types was reported," the FDA said. "Several different types of cancers occurred more frequently among patients treated with Belviq, including pancreatic, colorectal and lung cancer. During the trial, one additional cancer per 470 patients treated with the medication for one year was observed."

People who have already taken Belviq should stop taking it, but "the FDA is not recommending special screening for patients who have taken Belviq," Woodcock said.

More information

There's more on maintaining a healthy weight at the American Heart Association.